11 
In discussing the propcssal. Dr. Brill suggested that this proposed 
language be amended as follows: (1) following the word *plants", the 
words "and only DNA from such sources" would be added; and (2) a require- 
ment would be added that the experiments , and documentation that the 
organisms are not Known pathogens, nust be registered with the 1 oc:clI 
IBC; and (3) oontairinent for these experiments would be raised from PI 
to P2. It was noted that Dr. NovicK, in a letter, had suggested that 
containment be raised to P2. Dr. Brill moved acceptance of the proposal 
as amended. Dr. Feck>roff seconded the motion. 
Dr. Goldstein asked what type of dcxMnentaticxi wcxild be subnitted to the 
lcx:al IBC ocxTceming ncxpathogenicity. Dr. Brill replied that the inves- 
tigator should provide evictenoe frcm the literature that the organism is 
not pathogenic. 
Dr. Bems said that the proposed requirement for P2 had no scientific 
basis and moved to amend the language to require PI containment. 
Drs. Brill and Pedoroff acc^epted Dr. Bems* amendment. 
Dr. Bems then propcsed amendment which would cdiange the word "regis- 
tered" to the word "reviewed"; to Dr. Brill's amendment. Drs. Brill amd 
Pedoroff agreed. 
Mr. Ttomton asked Dr. Brill to restate his proposad as amended. 
Dr. Brill read the following amended motion: 
"Reccmbinant DNA experiments involving prokaryotes or lower eukaryotes 
nonpathogenic to man, amiiials, or plants, and coly DNA from such 
sources, can be cxxxlucted under PI cxxitainment cxmditions. The 
experiments must be reviewed by the lcx:ad. IBC with cScxximentatico 
that the organisms are not known pathogens." 
Dr. Gottesnan said she could not support the proposal ais: (1) It covers 
an enormous variety of organisms, (2) It cJoes not restricrt the type of 
vector to be used (e.g., oonjugative plasmids wcxjld be permissible), and 
(3) "Ncxpathogenic" may be defined differently by different IBCs. This 
proposal would represent a cJeparture from corrent Guideline philosophy. 
Dr. Gottesnan aigreed, however, that an expedited procedure for evaluating 
ocxitainment for experiments involving these organisms might be desirable. 
She suggested that prcpcxails involving norpathogenic prokaryotes and 
nonpathogenic lower eukaryotes might be reviewed by C»DA rather than by 
the full RAC. GRDA cxxjld consult with experts in the field. Dr. Mason 
also expressed cxxKom about the definiticxi of nonpathogenicity, and 
supported the ocxxopt of ORDA review. 
Dr. Gcjttesnan moved a substitute motion to extend Sec±ic3n 111-^3 of the 
Guidelines, vfiich currently allows recombinant DNA transfers between 
nonpathogenic prokaryotes at P3 containment, to include experiments 
with norpathogenic lower eukaryotes. Her substitute motion wbuld also 
( 39 ) 
